secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEAYA Biosciences, Inc. (IDYA)
CIK:        0001676725
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0000950170-25-102353
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEAYA Q2 net loss $77.5M; cash ~$992M; darovasertib PFS data on track for YE2025
--------------------------------------------------------------------------------

- Net loss of $77.5M for Q2 2025 vs $72.2M in Q1 2025; R&D expenses $74.2M, G&A $14.6M.
- Cash, cash equivalents and marketable securities ~$992M as of June 30, 2025, down from $1.05B at March 31, 2025.
- Darovasertib/crizotinib Phase 2/3 trial in 1L HLA-A2-negative MUM enrolled over 350 patients; median PFS data on track for YE2025 to potentially enable accelerated approval filing.
- Three IND submissions by YE2025: IDE892 (PRMT5), IDE034 (B7H3/PTK7 bispecific ADC), IDE574 (KAT6/7).
- IDEAYA to host R&D Day on Sept 8, 2025, with multiple clinical data updates including neoadjuvant darovasertib and IDE397 combo data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676725/000095017025102353/0000950170-25-102353-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676725/000095017025102353/idya-20250805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-102353

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer